Detailed Information on Publication Record
2024
Hand2 Immunohistochemistry in the Diagnosis of Paragangliomas and Other Neuroendocrine Neoplasms
SOUKUP, Jiri, Monika MANETHOVA, Vaclav STEJSKAL, Marie NOVAKOVA, Jaroslava DUSKOVA et. al.Basic information
Original name
Hand2 Immunohistochemistry in the Diagnosis of Paragangliomas and Other Neuroendocrine Neoplasms
Authors
SOUKUP, Jiri (203 Czech Republic), Monika MANETHOVA (203 Czech Republic), Vaclav STEJSKAL (203 Czech Republic), Marie NOVAKOVA (203 Czech Republic), Jaroslava DUSKOVA (203 Czech Republic), Helena HORNYCHOVA (203 Czech Republic), Maria HACOVA (203 Czech Republic), Iva STANICZKOVÁ ZAMBO (203 Czech Republic, belonging to the institution), Tomas ZELINKA (203 Czech Republic), Mikulas KOSAK (203 Czech Republic), Tomas CESAK (203 Czech Republic), David NETUKA (203 Czech Republic), Ales RYSKA (203 Czech Republic) and Filip GABALEC (203 Czech Republic)
Edition
Endocrine Pathology, Totowa, Humana Press INC, 2024, 1046-3976
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30109 Pathology
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 4.400 in 2022
Organization unit
Faculty of Medicine
UT WoS
001173128600001
Keywords in English
Hand2; dHand; Paraganglioma; Phox2B; GATA3; Neuroendocrine tumors
Tags
International impact, Reviewed
Změněno: 3/5/2024 14:46, Mgr. Tereza Miškechová
Abstract
V originále
Hand2 is a core transcription factor responsible for chromaffin cell differentiation. However, its potential utility in surgical pathology has not been studied. Thus, we aimed to investigate its expression in paragangliomas, other neuroendocrine neoplasms (NENs), and additional non-neuroendocrine tumors. We calibrated Hand2 immunohistochemistry on adrenal medulla cells and analyzed H-scores in 46 paragangliomas (PGs), 9 metastatic PGs, 21 cauda equina neuroendocrine tumors (CENETs), 48 neuroendocrine carcinomas (NECs), 8 olfactory neuroblastomas (ONBs), 110 well-differentiated NETs (WDNETs), 10 adrenal cortical carcinomas, 29 adrenal cortical adenomas, 8 melanomas, 41 different carcinomas, and 10 gastrointestinal stromal tumors (GISTs). Both tissue microarrays (TMAs) and whole sections (WSs) were studied. In 171 NENs, previously published data on Phox2B and GATA3 were correlated with Hand2. Hand2 was positive in 98.1% (54/55) PGs, but only rarely in WDNETs (9.6%, 10/104), CENETs (9.5%, 2/21), NECs (4.2%, 2/48), or ONBs (12.5%, 1/8). Any Hand2 positivity was 98.1% sensitive and 91.7% specific for the diagnosis of PG. The Hand2 H-score was significantly higher in primary PGs compared to Hand2-positive WDNETs (median 166.3 vs. 7.5; p < 0.0001). Metastatic PGs were positive in 88.9% (8/9). No Hand2 positivity was observed in any adrenal cortical neoplasm or other non-neuroendocrine tumors, with exception of 8/10 GISTs. Parasympathetic PGs showed a higher Hand2 H-score compared to sympathetic PGs (median H-scores 280 vs. 104, p < 0.0001). Hand2 positivity in NENs serves as a reliable marker of primary and metastatic PG, since other NENs only rarely exhibit limited Hand2 positivity.
Links
LM2023033, research and development project |
|